Table 6.
Simulated % ACPR28 with 90% confidence intervals for single dose combinations of artefenomel and PQP in non-vomiting African children ≤ 5 years old
| PQP adult-equivalent dose, mg | Artefenomel adult-equivalent dose, mg | ||||||
| 0 | 200 | 400 | 800 | 1200 | 1600 | ||
| 0 | NR (–) | 22 (14–32) | 39 (29–49) | 70 (59–79) | 86 (78–92) | 94 (88–97) | |
| 320 | 27 (18–37) | 35 (28–44) | 52 (45–59) | 79 (73–84) | 91 (86–94) | 96 (93–98) | |
| 640 | 40 (29–52) | 48 (39–58) | 64 (58–70) | 85 (81–88) | 94 (91–96) | 97 (95–99) | |
| 960 | 51 (38–64) | 59 (48–69) | 72 (65–78) | 89 (85–92) | 95 (93–97) | 98 (97–99) | |
| 1440 | 64 (49–76) | 70 (59–80) | 80 (73–86) | 92 (89–95) | 97 (95–98) | 99 (98–99) | |
| 2000 | 74 (59–85) | 79 (67–88) | 86 (80–91) | 95 (93–97) | 98 (97–99) | 99 (98–100) | |
| 2800 | 83 (70–91) | 86 (76–93) | 91 (85–95) | 97 (95–98) | 99 (98–100) | > 99 (99–100) | |
| 3600 | 88 (78–95) | 91 (83–96) | 94 (90–97) | 98 (96–99) | 99 (99–100) | > 99 (99–100) | |
For the stimulations, the identified age effect on artefenomel PK was not included; it was assumed, therefore, that exposures in the youngest patients were similar to those in the older age groups. NR not reported
Predicted ACPR28 > 95%; outcome predicted with a lower bound > 95%